SLGL ▲ +1.5% - Sol-Gel Technologies Ltd. $SLGL - Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome Sol-Gel Technologies rose 1.5% after announcing the completion of patient enrollment in its pivotal Phase 3 trial for SGT-610, an experimental treatment for Gorlin Syndrome. The achievement of the last patient's final visit represents a key milestone toward potential regulatory approval, as the company moves closer to data readout and submission. 17-SEP-2026 08:32 AM ET